These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20815890)

  • 21. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
    Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
    Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
    Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
    Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
    Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
    Hann HW
    Expert Opin Pharmacother; 2010 Sep; 11(13):2243-9. PubMed ID: 20698726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
    Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
    Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Tillmann HL; McHutchison JG
    N Engl J Med; 2008 Apr; 358(14):1517; author reply 1517-8. PubMed ID: 18385505
    [No Abstract]   [Full Text] [Related]  

  • 31. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
    Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Hadziyannis SJ
    Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
    Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ; Wang Y; Liaw YF; Hou J; Thongsawat S; Wan M; Moon YM; Jia J; Chao YC; Niu J; Leung N; Samuel D; Hsu CW; Bao W; Lopez P; Avila C
    Liver Int; 2011 May; 31(5):676-84. PubMed ID: 21457439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.
    Wu Y; Jie Y; Li X; Huang M; Li X; Shi H; Chen S; Zhang M; Ao Y; Yang F; Gao Z; Lin G; Chong Y
    Clin Res Hepatol Gastroenterol; 2016 Apr; 40(2):213-20. PubMed ID: 26598028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.
    Dai M; Xiao GM; Wang FL; Zhang JS; Li YM; Yang HZ
    J Int Med Res; 2015 Apr; 43(2):161-72. PubMed ID: 25687498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
    Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
    J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
    Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
    Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.